ACTIVE ABETA IMMUNIZATION IN VERVETS

长尾黑颚猴主动 ABETA 免疫接种

• 批准号: 7715450
• 负责人: CYNTHIA A LEMERE
• 金额: $ 5.52万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-05 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7715450
• 关键词: Abeta clearance; Adverse effects; Adverse event; Alzheimer' s Disease; Amyloid beta-Protein; Amyloid beta-Protein Precursor; Animal Model; Antigens; Caribbean natives; Caribbean region; Cerebrum; Clinical Trials; Cognition; Computer Retrieval of Information on Scientific Projects Database; Deposition; Engineering; Funding; Goals; Grant; Human; Immune response; Immunization; Immunotherapy; Institution; Length; Meningoencephalitis; Nervous system structure; Patients; Proteins; Research; Research Personnel; Resources; Source; Training; United States National Institutes of Health; Vaccination; Vaccines; age related; behavior test; cognitive function; improved; mouse model; nonhuman primate; novel; prevent; vaccine efficacy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Active Abeta Immunization: Abeta immunotherapy has potential for preventing and possibly treating Alzheimer's disease (AD) in humans. Studies in genetically-engineered AD mouse models have consistently demonstrated efficacy of the Abeta vaccine both in lowering CNS Abeta and improving cognition without any adverse effects. However, the first human clinical trial was halted due to meningoencephalitis in approximately 6% of patients; recognition of the full-length Abeta immunogen as a self-protein may have attributed to these adverse events. Non-human primates, including Caribbean vervets (Chlorocebus aethiops), have the same amyloid precursor protein (APP) and Abeta as humans, and have age-related cerebral plaque deposition. Thus, they may serve as a better animal model for studying Abeta clearance and immune responses to Abeta vaccination. We have trained vervets for behavioral testing of cognitive functions and began Abeta vaccination in June 2006. Our goals are to characterize the humoral and cellular immune responses to a novel Abeta vaccine and to determine the vaccine's efficacy in lowering Abeta within the nervous system and improving cognition.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 主动Abeta免疫：Abeta免疫疗法具有预防和可能治疗人类阿尔茨海默病（AD）的潜力。 在基因工程AD小鼠模型中的研究一致证明了Abeta疫苗在降低CNS Abeta和改善认知方面的功效，而没有任何副作用。 然而，第一个人类临床试验由于约6%的患者的脑膜脑炎而停止;全长Abeta免疫原作为自身蛋白的识别可能归因于这些不良事件。非人类灵长类动物，包括加勒比海长尾猴（Chlorocebus aethiops），具有与人类相同的淀粉样前体蛋白（APP）和Abeta，并具有与年龄相关的脑斑块沉积。 因此，它们可以作为研究Abeta清除和对Abeta疫苗接种的免疫应答的更好的动物模型。 我们已经训练了黑尾长尾雉进行认知功能的行为测试，并于2006年6月开始接种Abeta疫苗。我们的目标是表征对新型Abeta疫苗的体液和细胞免疫应答，并确定疫苗在降低神经系统内Abeta和改善认知方面的功效。